Neuraxial block, death and serious cardiovascular morbidity in the POISE trial † †This article is accompanied by Editorial III.

Neuraxial block, death and serious cardiovascular morbidity in the POISE trial

Neuraxial block, death and serious cardiovascular morbidity in the POISE trial†

K. Leslie1,2*, P. Myles4,5,7, P. Devereaux8,9,10, E. Williamson3,6, P. Rao-Melancini11, A. Forbes6, S. Xu12, P. Foex13, J. Pogue11, M. Arrieta14,15, G. Bryson16, J. Paul17, M. Paech18,19, R. Merchant20, P. Choi21,22, N. Badner23, P. Peyton24,25, J. Sear13 and H. Yang26 1 Department of Anaesthesia and Pain Management, Royal Melbourne Hospital, Melbourne, Australia 2 Department of Pharmacology an...

Neuraxial block, death, and serious cardiovascular morbidity in the POISE trial.

BACKGROUND This post hoc analysis aimed to determine whether neuraxial block was associated with a composite of cardiovascular death, non-fatal myocardial infarction (MI) and non-fatal cardiac arrest within 30 days of randomization in POISE trial patients. METHODS A total of 8351 non-cardiac surgical patients at high risk of cardiovascular complications were randomized to β-blocker or placebo...

Nitrous oxide and cardiovascular outcome: perspective from the POISE trial.

Editorial comment regarding H5N1 influenza article in this issue.

In this issue of the Journal of Infectious Diseases, Sakabe et al report that the polymerase acidic (PA) protein component of the H5N1 influenza RNA-dependent RNA polymerase affects cytokine production in human macrophages and may be important in determining pathogenicity in mice [1]. They imply that PA may be relevant to the increased mortality mediated by hypercytokinemia in H5N1 infection in...